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Study Name,
Year Location No of patients Comparison Primary Outcome
Use of
Retrievable
Stents
Mr Clean, 2015 Netherlands
(16 centers)
500 Mechanical
treatment,
delivery of a
thrombolytic
agent, or both vs.
conventional
therapy
Modiﬁed Rankin
Score at 90 days
97%
SWIFT-PRIME,
2015
International (90
centers)
196 IV t-PA þ Solitaire vs.
IV t-PA alone
Modiﬁed Rankin
Score at 90 days
100%
EXTEND-IA, 2015 Australia and New
Zealand
(14 centers)
70 Endovascular
thrombectomy
with retrievable
stent vs
conventional
therapy
Reperfusion at 24
hours
Early neurologic
improvement
(8-point
reduction on
the NIHSS or a
score of 0 or 1)
100%
ESCAPE,
2015
International (44
centers)
315 Mechanical
treatment vs.
conventional
therapy
Modiﬁed Rankin
Score at 90 days
86.1%
REVASCAT,
2015
Spain
(4 centers)
206 Endovascular
thrombectomy
with retrievable
stent vs
conventional
therapy
Modiﬁed Rankin
Score at
90 days
100%
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with stent retrievers appears as a safe and effective therapeutic option
for acute ischemic stroke due to large vessel occlusion.
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BACKGROUND Carotid artery stenting (CAS) has evolved into a viable
alternative for the treatment of symptomatic and asymptomatic high-
grade carotid artery stenosis, particularly in patients considered to be
at a high surgical risk for carotid endarterectomy (CEA). There is
limited data on the outcomes of patients with stage 5 chronic kidney
disease (CKD) (GFR<15 mL/min/1.73 m2 or dialysis) undergoing CEA or
CAS.
METHODS The Healthcare Cost and Utilization Project’s National
Inpatient Sample was screened for hospital admissions of patientsundergoing CAS and CEA from 2003-2012. Baseline clinical charac-
teristics and outcomes were identiﬁed in patients with stage 5 CKD.
The primary outcome was major adverse cardiac and cerebrovascular
events (MACCE) (in-hospital death, acute myocardial infarction and
acute cerebrovascular accident (CVA).
RESULTS Our study population consisted of 1,723 patients that un-
derwent CEA and 544 patients that underwent CAS. Patients under-
going CAS were younger and had signiﬁcantly lower rates of coronary
artery disease, hypertension and hyperlipidemia (Table). CAS patients
experienced signiﬁcantly higher rates of MACCE compared with
patients that underwent CEA, mainly driven by a higher rate of in-
hospital strokes (Table). In a multivariable analysis, CAS (OR 1.53,
95% CI 1.19-1.98) was independently predictive of MACCE.
Table 1. Demographics, clinical characteristics and in-hospital outcomesCEA CASp valuen[ 1,723 n[ 544Age (years  SD) 69.2 (9.6) 66.7 (12.0) <0.001
Race: White (%) 1,007 (70.3%) 280 (60.9%) 0.004Coronary artery
disease1,039 (60.3%) 296 (54.4%) 0.015Peripheral vascular
disease (%)492 (28.6%) 155 (28.5%) 0.963COPD (%) 329 (19.1%) 96 (17.7%) 0.431Diabetes mellitus (%) 999 (58.0%) 320 (58.8%) 0.737Hypertension (%) 1,646 (95.5%) 508 (93.4%) 0.047Hyperlipidemia (%) 812 (47.1%) 217 (39.9%) 0.003MACCE (%) 236 (13.7%) 106 (19.5%) 0.001In-hospital AMI (%) 83 (4.8%) 31 (5.7%) 0.422In-hospital stroke (%) 145 (8.4%) 77 (14.2%) <0.001In-hospital death (%) 33 (1.9%) 20 (3.7%) 0.014CONCLUSIONS In patients with stage 5 CKD (GFR<15 mL/min/1.73 m2
or dialysis) undergoing carotid artery revascularization, CAS was
associated with higher rates of in-hospital MACCE, driven by higher
mortality and stroke rates when compared with CEA.
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BACKGROUND Although published studies have reported inverse
association between hospital volume and outcomes of coronary in-
terventions, there is sparse data on the impact of hospital volume on
percutaneous non-coronary atherectomy. An aim of study is to see
inﬂuence of hospital volume on the In-hospital mortality, discharge
disposition, Amputation rates and peri-procedural complications of
percutaneous peripheral atherectomy.
METHODS Using Nationwide Inpatient Sample database from
Healthcare Cost and Utilization Project of 2012 year. We identiﬁed
peripheral vascular disease of lower limbs for age >¼ 18 years. We
sought for only peripheral atherectomy and its outcomes using vali-
dated ICD 9 codes. Annual hospital volume was calculated using
unique identiﬁcation numbers and then divided into tertiles for
analysis. Multivariate logistic regression models were generated in
order to identify the independent predictors of outcomes.
RESULTS We identiﬁed a total of 21,015 procedures with mean age
69.53 years, 56% male and 61% were whites. Results shown the mean
Deyo’s Modiﬁed Charlson score was 2.2, Hypertension (79%), Diabetes
(54%), Congestive heart failure (18%) and 10% were obese. Results
shown overall amputation rates (7.68%), In-hospital mortality
(1.38%), and 22.25% were discharged to rehab/long-term facilities.
Importantly, highest hospital volume tertile had a signiﬁcantly lower
in-hospital mortality (OR: 0.42, 95% CI 0.30-0.57, p<0.0001), com-
bined end-point of mortality and complications (OR: 0.53, 95% CI
